Free Trial

10 Best Penny Stocks to Buy Now - 7 of 10

 
 

Immunic (NASDAQ:IMUX)

Number of Upgrades from Top-Ranked Analysts
4 (in the last 90 days)
Consensus Rating
Buy
Rating Score
3.3
Ratings Breakdown
8 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$11.60 (1,511.1% Upside)

About Immunic

Immunic logoImmunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. More about Immunic
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
6/5/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$10.00
5/29/2025D. Boral CapitalLower Price TargetBuy ➝ Buy$17.00 ➝ $10.00
5/23/2025B. RileyReiterated RatingBuy ➝ Buy$6.00 ➝ $5.00
5/16/2025William BlairReiterated RatingOutperform
5/1/2025HC WainwrightReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
4/30/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$17.00 ➝ $17.00
4/16/2025B. RileyReiterated RatingBuy ➝ Buy$6.00 ➝ $6.00
4/15/2025HC WainwrightReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
4/10/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$17.00 ➝ $17.00
4/1/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$17.00 ➝ $17.00